References
- Baxter E J, Scott L M, Campbell P J, East C, Fourouclas N, Swanton S, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054–1061
- James C, Ugo V, Le Couedic J P, Staerk J, Delhommeau F, Lacout C, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005; 434: 1144–1148
- Kralovics R, Passamonti F, Buser A S, Teo S S, Tiedt R, Passweg J R, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352: 1779–1790
- Levine R L, Wadleigh M, Cools J, Ebert B L, Wernig G, Huntly B J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005; 7: 387–397
- Antonioli E, Guglielmelli P, Pancrazzi A, Bogani C, Verrucci M, Ponziani V, et al. Clinical implications of the JAK2 V617F mutation in essential thrombocythemia. Leukemia 2005; 19: 1847–1849
- Campbell P J, Scott L M, Buck G, Wheatley K, East C L, Marsden J T, et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet 2005; 366: 1945–1953
- Wolanskyj A P, Lasho T L, Schwager S M, McClure R F, Wadleigh M, Lee S J, et al. JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance. Br J Haematol 2005; 131: 208–213
- Campbell P J, Griesshammer M, Dohner K, Dohner H, Kusec R, Hasselbalch H C, et al. V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis. Blood 2006; 107: 2098–2100
- Tefferi A, Lasho T L, Schwager S M, Steensma D P, Mesa R A, Li C Y, et al. The JAK2 tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates. Br J Haematol 2005; 131: 320–328
- Jones A V, Kreil S, Zoi K, Waghorn K, Curtis C, Zhang L, et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 2005; 106: 2162–2168
- Steensma D P, Dewald G W, Lasho T L, Powell H L, McClure R F, Levine R L, et al. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both “atypical” myeloproliferative disorders and the myelodysplastic syndrome. Blood 2005; 106: 1207–1209
- Wernig G, Mercher T, Okabe R, Levine R L, Lee B H, Gilliland D G. Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood 2006; 107: 4274–4281
- Levine R L, Belisle C, Wadleigh M, Zahrieh D, Lee S, Chagnon P, et al. X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoiesis. Blood 2006; 107: 4139–4141
- Tefferi A, Lasho T L, Schwager S M, Strand J S, Elliott M, Mesa R, et al. The clinical phenotype of wild-type, heterozygous, and homozygous JAK2(V617F) in polycythemia vera. Cancer 2006; 106: 631–635
- Lippert E, Boissinot M, Kralovics R, Girodon F, Dobo I, Praloran V, et al. The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera. Blood 2006; 108: 1865–1867
- Vardiman J W, Brunning R D, Harris N L. WHO histological classification of chronic myeloproliferative diseases. World Health Organization Classification of Tumors: Tumours of the Haematopoietic and Lymphoid Tissues, E S Jaffe, N L Harris, H Stein, J W Vardiman. IARC Press, LyonFrance 2001; 17–44